Clinical trial
High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem…
NCT00389766 · Children's Cancer and Leukaemia Group, Other · Withdrawn
Key facts
| NCT number | NCT00389766 |
|---|---|
| Title | High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma |
| Official title | International Phase II Studies of I-mIBG in Combination With Topotecan and Peripheral Blood Stem Cell Rescue for (A) Primary Resistant High Risk Neuroblastoma and (B) Relapsed Stage 4 Neuroblastoma |
| Lead sponsor | Children's Cancer and Leukaemia Group, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Drug, Procedure |
| Interventions | iodine I 131 metaiodobenzylguanidine, topotecan hydrochloride, chemotherapy, peripheral blood stem cell transplantation, radioisotope therapy, radionuclide imaging, radiosensitization, total-body irradiation |
| Enrollment | 0 |
| Start date | Jul 1, 2008 |
| Primary completion | Jul 1, 2008 |
| First posted | Oct 19, 2006 |
| Last update posted | Jul 10, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: